Cipla (CPLFY) Cash-to-Debt : N/A (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Cipla Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cipla's cash to debt ratio for the quarter that ended in Dec. 2023 was N/A.

The historical rank and industry rank for Cipla's Cash-to-Debt or its related term are showing as below:

CPLFY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28 Med: 0.62 Max: 7.69
Current: 7.47

During the past 13 years, Cipla's highest Cash to Debt Ratio was 7.69. The lowest was 0.28. And the median was 0.62.

CPLFY's Cash-to-Debt is ranked better than
74.62% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs CPLFY: 7.47

Cipla Cash-to-Debt Historical Data

The historical data trend for Cipla's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cipla Cash-to-Debt Chart

Cipla Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

0.61

0.57

1.86

4.39

7.69

Cipla Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															N/A	7.69	N/A	7.47	N/A

Competitive Comparison of Cipla's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Cipla's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cipla's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cipla's Cash-to-Debt falls into.

Cipla Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cipla's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	761.314	/	(73.673	+	25.383)
	=	7.69

Cipla's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Cipla (OTCPK:CPLFY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cipla Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cipla's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cipla (CPLFY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cipla Ltd (OTCPK:CPLFY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CIPLA:India 500087:India

Address

Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013

Website

https://www.cipla.com

Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large global presence. Cipla's growth strategy focuses on new product launches. It has two segments Pharmaceuticals and new ventures.